Effect of niacin on LDL particle size and cardiovascular outcomes in statin-treated patients (HPS2-THRIVE)
HPS2-THRIVE Collaborative Group
Published in New England Journal of Medicine
Methodology
Large randomized placebo-controlled trial of extended-release niacin plus laropiprant added to statin therapy, with lipid subfraction and clinical event outcomes.
Key Findings
Niacin improved lipid fractions including LDL particle characteristics but produced no reduction in major vascular events and increased serious adverse events.
Conclusions
Favourable LDL particle changes did not translate into clinical benefit, undermining particle-size surrogates.
Limitations
Laropiprant co-administration may contribute to adverse events; population already well treated with statins.
Supplements Studied
Niacin improved lipid fractions including LDL particle characteristics but produced no reduction in major vascular events and increased serious adverse events.
Outcomes Measured
Niacin improved lipid fractions including LDL particle characteristics but produced no reduction in major vascular events
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.